OMGA vs. SGMO, KPTI, CMRX, MOLN, PSNL, EDIT, ALEC, FATE, OCGN, and ALLO
Should you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Sangamo Therapeutics (SGMO), Karyopharm Therapeutics (KPTI), Chimerix (CMRX), Molecular Partners (MOLN), Personalis (PSNL), Editas Medicine (EDIT), Alector (ALEC), Fate Therapeutics (FATE), Ocugen (OCGN), and Allogene Therapeutics (ALLO). These companies are all part of the "medical" sector.
Sangamo Therapeutics (NASDAQ:SGMO) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
Sangamo Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
Sangamo Therapeutics has a net margin of -1,749.06% compared to Sangamo Therapeutics' net margin of -1,868.35%. Sangamo Therapeutics' return on equity of -136.04% beat Omega Therapeutics' return on equity.
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Omega Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. Omega Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sangamo Therapeutics received 416 more outperform votes than Omega Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Omega Therapeutics an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics currently has a consensus target price of $5.67, suggesting a potential upside of 875.67%. Omega Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 405.05%. Given Omega Therapeutics' higher possible upside, equities analysts plainly believe Sangamo Therapeutics is more favorable than Omega Therapeutics.
In the previous week, Omega Therapeutics had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Omega Therapeutics and 0 mentions for Sangamo Therapeutics. Omega Therapeutics' average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.
Summary
Omega Therapeutics beats Sangamo Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Omega Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omega Therapeutics Competitors List
Related Companies and Tools
